Evaluation of economic burden with biologic treatments in Crohn’s disease patients: A mirror image study using an insurance database in Japan

Biologics are recommended in Japan to treat moderate to severe Crohn’s Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab’s approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated direct costs...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazaki, Celine, Katsumasa, Nagano, Huang, Kuan Chih, Liu, Yan Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289035/
https://www.ncbi.nlm.nih.gov/pubmed/34280242
http://dx.doi.org/10.1371/journal.pone.0254807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289035/
https://www.ncbi.nlm.nih.gov/pubmed/34280242
http://dx.doi.org/10.1371/journal.pone.0254807

Ejemplares similares